09/12/2025
A significant advancement for the lupus community across Europe! The 𝐄𝐮𝐫𝐨𝐩𝐞𝐚𝐧 𝐂𝐨𝐦𝐦𝐢𝐬𝐬𝐢𝐨𝐧 has officially approved Roche’s 𝐆𝐚𝐳𝐲𝐯𝐚/𝐆𝐚𝐳𝐲𝐯𝐚𝐫𝐨 𝐰𝐢𝐭𝐡 𝐌𝐌𝐅 for adults with active lupus nephritis—supported by strong clinical evidence showing improved kidney response, reduced steroid use and better long-term disease control.
For patients, families and healthcare providers, this marks a hopeful step toward delaying the progression to end-stage kidney disease and improving quality of life.
We’re committed to bringing the latest pharmaceutical breakthroughs to our community.
🔗 𝐋𝐞𝐚𝐫𝐧 𝐦𝐨𝐫𝐞 𝐨𝐧 𝐨𝐮𝐫 𝐰𝐞𝐛𝐬𝐢𝐭𝐞: https://www.pharmafocuseurope.com/pharma-exclusives/press-releases/european-commission-approves-roches